Hansa Biopharma AB (publ) HNSA
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Hold; consider scaling in gradually on weakness into/after the H1 report and CMD, while keeping sizing constrained due to binary FDA risk (e.g., 5–10% of a biotech allocation depending on risk tolerance).
Value remains in the FDA decision and US launch while the SERB deal has strengthened the cash position.
Sentiment has strengthened from concrete steps toward the US capital markets while dilution risk increases.
HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 23 Aug 2026 — ▼ Dilution risk was raised from low to medium following the announced directed share issue and new US depositary receipts.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (8) — follow the company freeAbout the company
Hansa Biopharma is a biotech company developing and commercializing immunomodulating enzyme therapies. Its lead product Idefirix (imlifidase) enables desensitization ahead of kidney transplantation in highly sensitized patients, alongside a pipeline in autoimmune and transplant-related indications. The company is commercial/growth-stage but not yet profitable and is highly dependent on U.S. regulatory and commercial execution.
Bull case
Steps toward a Nasdaq listing broaden the institutional investor base and secure financing ahead of a potential US launch.
Bear case
The announced directed share issue and new depositary receipts entail imminent dilution risk.
Why this signal
Value remains in the FDA decision and US launch while the SERB deal has strengthened the cash position.
Recent news
The extraordinary general meeting on 22 September approved two new board members, a long-term RSU program and an amendment to the articles with an exclusive US forum clause as a step toward ADS listing.